entr-601-44
·Code: ENTR-601-44
entr-601-44: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Entrada Therapeutics, Inc. (TRDA) | Phase 1/Phase 2 |
Clinical Trials (1)
A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping With an Initial Multiple Ascending Dose Part A to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ENTR-601-44, Followed by Part B to Evaluate the Safety and Efficacy of ENTR-601-44 (ELEVATE-44)
Frequently asked questions
Who is developing entr-601-44?
entr-601-44 is being developed by Entrada Therapeutics, Inc..
How many clinical trials involve entr-601-44?
BioSniper tracks 1 clinical trial involving entr-601-44.
Get deeper analysis on entr-601-44
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis